Out of 8 analysts covering Axovant Sciences (NYSE:AXON), 7 rate it “Buy”, 1 “Sell”, while 0 “Hold”. This means 88% are positive. Axovant Sciences was the topic in 3 analyst reports since September 25, 2015 according to StockzIntelligence Inc. Below is a list of Axovant Sciences Ltd (NYSE:AXON) latest ratings and price target changes.
08/01/2016 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Initiate
22/10/2015 Broker: Piper Jaffray Rating: Overweight Initiate
The stock decreased 6.54% or $0.83 on April 8, hitting $11.86. About 170,607 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has declined 10.08% since September 2, 2015 and is downtrending. It has underperformed by 15.15% the S&P500.
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.11 billion. The Firm is focused on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. It currently has negative earnings. The Firm develops RVT-101, a product candidate for the treatment of Alzheimer’s disease and other forms of dementia.
Axovant Sciences Ltd - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.